Literature DB >> 2990391

Effects of activated serum factor on the induction of Epstein-Barr virus antigens and cell differentiation.

K Roubalová, E Anisimová, J Roubal.   

Abstract

n-Butyrate and 12-0-tetradecanoylphorbol-13-acetate (TPA) have been shown to be potent inducers of Epstein-Barr virus (EBV) antigen synthesis (10, 18) and cell differentiation (1,2). Activated serum factor (SF) has also been reported to induce virus antigen synthesis and moreover it is capable of cooperative action with other inducers (5). We have demonstrated with an EBV-carrying lymphoma cell line (Raji) that activated SF can also induce the appearance of some cellular alterations, specific for early steps of the productive virus cycle in a low proportion of cells. In addition cell differentiation towards plasma cell was noted in about 8 per cent of SF-treated cells. It was confirmed that activated SF enhances the induction of virus antigens by n-butyrate or TPA as detected by the immunofluorescence technique. It was shown that it also potentiates the development of virus-induced changes in cellular morphology and the cell differentiation induced by these drugs. This effect was more pronounced in combination with TPA than with butyrate. Possible relationships between cell differentiation and virus-antigen expression are discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2990391     DOI: 10.1007/bf01317008

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  18 in total

1.  Enhancement of Epstein-Barr virus replication in producer cell lines by a combination of low temperature and corticosteroids.

Authors:  I T Magrath; P A Pizzo; L Novikovs; A S Levine
Journal:  Virology       Date:  1979-09       Impact factor: 3.616

2.  Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate.

Authors:  J Luka; B Kallin; G Klein
Journal:  Virology       Date:  1979-04-15       Impact factor: 3.616

3.  Tumor initiators and promoters in the induction of Epstein-Barr virus.

Authors:  H zur Hausen; G W Bornkamm; R Schmidt; E Hecker
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

4.  Activation of Epstein-Barr virus by 5-bromodeoxyuridine in "virus-free" human cells (complement-fixing antigen-immunofluorescence-leukocytes).

Authors:  P Gerber
Journal:  Proc Natl Acad Sci U S A       Date:  1972-01       Impact factor: 11.205

5.  Immunofluorescence in cells derived from Burkitt's lymphoma.

Authors:  G Henle; W Henle
Journal:  J Bacteriol       Date:  1966-03       Impact factor: 3.490

6.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

7.  Ultrastructural changes induced by influenza viruses in permissive and nonpermissive cells.

Authors:  E Anismová; E Tucková; V Vonka; H Závadová
Journal:  Virology       Date:  1977-03       Impact factor: 3.616

8.  Epstein-Barr virus induction by a serum factor. I. Induction and cooperation with additional inducers.

Authors:  G Bauer; P Höfler; H Zur Hausen
Journal:  Virology       Date:  1982-08       Impact factor: 3.616

9.  Effects of n-butyrate and phorbol ester (TPA) on induction of Epstein-Barr virus antigens and cell differentiation.

Authors:  E Anisimová; K Prachová; J Roubal; V Vonka
Journal:  Arch Virol       Date:  1984       Impact factor: 2.574

10.  Epstein-barr virus induction by a serum factor: IV. Ubiquitous occurrence of the factor within vertebrates and its interaction with defined lymphoid cell lines.

Authors:  P Wittmann; P Höfler; G Bauer
Journal:  Int J Cancer       Date:  1982-10-15       Impact factor: 7.396

View more
  2 in total

1.  Chemically purified serum factor can induce both Epstein-Barr virus antigen synthesis and cell differentiation.

Authors:  E Anisimová; K Roubalová; G Bauer; J Roubal
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

2.  Antibodies to Epstein-Barr virus in patients with nasopharyngeal carcinoma in Northern Ireland.

Authors:  P V Coyle; D Wyatt; J H Connolly; G A Lynch
Journal:  Ir J Med Sci       Date:  1987-06       Impact factor: 1.568

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.